Intra-cellular therapies reports fourth quarter and full-year 2024 financial results

Fourth quarter 2024 caplyta net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
ITCI Ratings Summary
ITCI Quant Ranking